New keytruda copycat tested in melanoma trial
Disease control
Ongoing
This study tests whether FYB206, a biosimilar (or copycat) of the cancer drug Keytruda, works similarly in the body. It involves 96 people with stage IIB/IIC or III melanoma that was completely removed by surgery. Participants receive either FYB206 or Keytruda, and researchers co…
Phase: PHASE1 • Sponsor: Formycon AG • Aim: Disease control
Last updated Jun 26, 2026 14:08 UTC